Register for OBR daily




To find out more about a company click on the company name to see a brief profile.

OBR Finance Top 5 Winners

MTP $4.40 0.6800 +18.28%
ARGS $4.86 0.2200 +4.74%
IMDZ $6.85 0.2900 +4.42%
SNSS $0.92 0.0300 +3.37%
CCXI $5.00 0.1600 +3.31%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

OBR Finance Top 5 Losers

NYMX $3.73 -1.1600 -23.72%
XBIT $13.08 -1.1800 -8.27%
MNKD $0.79 -0.0469 -5.61%
MNTA $12.20 -0.5100 -4.01%
VBLT $4.07 -0.1700 -4.01%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content.

Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

<< First | < Prev | 877 | 878 | 879 | 880 | 881 | 882 | 883 | 884 | 885 | 886 | Next > | Last >>

Breakthrough In The Understanding Of How Pancreatic Cancer Cells Ingest Nutrients Points To New Drug Target

(NYU Langone Medical Center) May 13, 2013 - In a landmark cancer study published online in Nature, researchers at NYU School of Medicine have unraveled a longstanding mystery about how pancreatic tumor cells feed themselves, opening up new therapeutic possibilities for a notoriously lethal disease with few treatment options.
read press release 



Researchers Discover Master Regulator That Drives Majority of Lymphoma

(Weill Cornell Medical College) May 13, 2013 - A soon-to-be-tested class of drug inhibitors were predicted to help a limited number of patients with B-cell lymphomas with mutations affecting the EZH2 protein.
read press release 



Study Identifies Possible New Acute Leukemia Marker Treatment Target

(OSUCCC - James) May 12, 2013 - A study has identified microRNA-155 as a new independent prognostic marker and treatment target in patients with acute myeloid leukemia that has normal-looking chromosomes under the microscope (that is, cytogenetically normal acute myeloid leukemia, or CN-AML).
read press release 



Leap in Leukemia Treatment Reported by Dartmouth Researchers

(Dartmouth-Hitchcock) May 13, 2013 - Doctors at Dartmouth-Hitchcock's Norris Cotton Cancer Center (NCCC) have found a combination of drugs to potentially treat chronic lymphocytic leukemia (CLL) more effectively.
read press release 



Op-Ed: My Medical Choice

(New York Times) May 14, 2013 - Opening a conversation on women's health.
read article 



Women Have New Options for Breast Cancer Surgery

(New York Times/Associated Press) May 14, 2013 - Treating breast cancer almost always involves surgery, and for years the choice was just having the lump or the whole breast removed. Now, new approaches are dramatically changing the way these operations are done, giving women more options, faster treatment, smaller scars, fewer long-term side effects and better cosmetic results.
read article 



Medicare Overpaid $529 Million for Anemia Drugs in 2011 - Report

(Fox Business/Dow Jones Newswires) May 10, 2013 - Medicare paid $529 million more than it should have for antianemia drugs used in the treatment of kidney dialysis patients, a new government report finds, putting further pressure on regulators to reduce its payments for drugs manufactured by Amgen Inc. and others.
read article 



2 New Diseases Could Both Spark Global Outbreaks

(BloombergBusinessweek/Associated Press) May 13, 2013 - Two respiratory viruses in different parts of the world have captured the attention of global health officials ? a novel coronavirus in the Middle East and a new bird flu spreading in China.
read article 



Johnson & Johnson Unit Gets Priority Review for Simeprevir NDA

(Morningstar/Dow Jones Newswires) May 13, 2013 - Johnson & Johnson unit Janssen Research and Development LLC said the U.S. Food and Drug Administration has granted priority review to its new drug application for simeprevir, its investigational treatment of genotype 1 chronic hepatitis C in adult patients with compensated liver disease.
read article 



Analysis: Drugmakers Face More Scrutiny of Discordant U.S. Prices

(Reuters) May 10, 2013 - The world's biggest drug makers have for years enjoyed rich premiums for their medicines in the U.S. market. Those days may be coming to an end.
read article 



Biohit Targets China as Key Market for Cancer-Prevention

(Bloomberg) May 13, 2013 - Biohit Oyj, the Finnish health-care company whose shares have gained 71 percent this year, sees China as a promising market for the Acetium product to prevent stomach cancer, Chief Executive Officer Semi Korpela said.
read article 



Curis Announces Approval of Erivedge Anti-Cancer Drug in Australia

(Pharmaceutical Business Review) May 13, 2013 - Oncology-focused company Curis has announced the approval of Erivedge (vismodegib) in Australia for the treatment of metastatic basal cell carcinoma, or with locally advanced basal cell carcinoma in adult patients who are not suitable for surgery and/or radiation therapy.
read article 



The Cancer Institute of New Jersey Celebrates Its Nurses During Oncology Nursing Month

(CINJ) May 10, 2013 - To celebrate the dedication of these professionals, The Cancer Institute of New Jersey this week honored members of its nursing team with its annual Oncology Nursing Excellence Awards during the Elizabeth Gibby Osborne Lecture.
read press release 



McKesson Specialty Health Collaborates with Oncologists to Develop New Oncology-Specific iKnowMed Generation 2

(The US Oncology Network) May 13, 2013 - McKesson Specialty Health announced today the launch of iKnowMed Generation 2SM, a powerful web-based electronic health record (EHR) developed in collaboration with oncologists.
read corporate press release 



UNM Cancer Center Participating in National Clinical Trial

(UNM Cancer Center) May 6, 2013 - The University of New Mexico Cancer Center is among a few select institutions nationwide participating in a Phase 3 clinical trial studying a novel treatment for men with newly diagnosed, localized prostate cancer.
read press release 



NIH Releases Additional Information on FY 2013 Funding Policies Under Sequester

(ASH) May 11, 2013 - Because the Congress was unable to reach an agreement on how to reduce the deficit, President Obama issued an order implementing the automatic, across-the-board spending cuts known as "sequestration" on March 1, 2013.
read article 



ASCO Sequestration Impact Survey: One Month Out, Sequestration Affecting Care of Medicare Cancer Patients

(ASCO in Action) May 10, 2013 - A new ASCO survey of U.S. oncology practices shows the automatic two percent budget cut to Medicare chemotherapy drug reimbursement under sequestration is already having a significant impact on care for people with cancer just one month after the federal funding reduction went into effect.
read article 



Medicare to Cover Genomic Health's Oncotype DX Breast Cancer Test for DCIS

(GenomeWeb News) May 13, 2013 - Genomic Health said after the close of the market on Friday that the national Medicare contractor for the firm's Oncotype DX breast cancer test has expanded Medicare coverage for the test.
read article 



MorphoSys Initiates Phase 2 Study of Anti-CD19 Antibody MOR208 in Non-Hodgkin's Lymphoma

(Yahoo! Finance) May 13, 2013 - MorphoSys AG announced today that it has dosed the first patient in a Phase 2 clinical trial of MOR208 in Non-Hodgkin's Lymphoma (NHL).
read article 



EMCTO 2013 News: Findings Support the Value of Tumour Rebiopsy in NSCLC Patients

(ESMO) May 10, 2013 - Nearly half of patients with acquired resistance to tyrosine kinase inhibitor treatment developed mutations in T790M over the course of treatment.
read press release 



EMCTO 2013 News: Enobosarm Improves Muscle Wasting Experienced by Patients with NSCLC

(ESMO) May 10, 2013 - Per protocol safety review of unblinded safety data support two pivotal phase III clinical trials of enobosarm that are ongoing to determine the prevention and treatment of muscle wasting in patients with advanced NSCLC.
read press release 



EMCTO 2013 News: First-Line Gefitinib Effective and Well Tolerated in Caucasian Patients with EGFR Mutation-Positive NSCLC

(ESMO) May 10, 2013 - Phase IV study of gefitinib used as first-line treatment in Caucasian patients with epidermal growth factor receptor (EGFR) mutation-positive locally advanced/metastatic non-small cell lung cancer (NSCLC) indicate the treatment is effective and well tolerated.
read press release 



EMCTO News: Study of Simultaneous Occurrence of EGFR Mutations and HER2 Gene Amplifications in Large Series of NSCLC

(ESMO) May 10, 2013 - Recently, HER2 amplification was recognised as a mechanism of acquired resistance to EGFR-TKI that occurs in a subset of tumours lacking the acquired, somatic resistance EGFRT790M mutation.
read press release 



EMCTO News: Meta-Analysis Slightly Favours Platinum-Based First-Line Treatment in Patients with Advanced/Metastatic NSCLC

(ESMO) May 10, 2013 - Several meta-analysis conducted in the past suggest that survival of patients with advanced non-small cell lung cancer (NSCLC) is improved if first-line chemotherapy includes platinum derivatives.
read press release 



EMCTO News: Different Survival Outcome Following Diagnosis of Metastatic Bone Disease Shown for EGFR Mutated NSCLC Patients in Small Retrospective Study

(ESMO) May 10, 2013 - The incidence of metastatic bone disease or brain metastasis was not different between EGFR mutated, KRAS mutated and KRAS/EGFR wild type (wt) patients in small, retrospective study performed by Dutch investigators.
read press release